Related Experiment Video
Updated: May 20, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination
Abstract:
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a tyrosine kinase oncogene responsible for the pathogenesis of the majority of human ALK-positive lymphomas. We recently reported that it activated the Rac1 GTPase in anaplastic large-cell lymphoma (ALCL), leading to Rac-dependent formation of active invadopodia required for invasiveness. Herein, we went further into the study of this pathway and used the inhibitor of Rac, NSC23766, to validate its potential as a molecular target in ALCL in vitro and in vivo in a xenograft model and in a conditional model of NPM-ALK transgenic mice. Our data demonstrate that Rac regulates important effectors of NPM-ALK-induced transformation such as Erk1/2, p38 and Akt. Moreover, inhibition of Rac signaling abrogates NPM-ALK-elicited disease progression and metastasis in mice, highlighting the potential of small GTPases and their regulators as additional therapic targets in lymphomas.
Insights
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) drives lymphoma by activating Rac1 GTPase. Inhibiting Rac signaling halts cancer progression and metastasis, offering new therapeutic targets for lymphomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogene in ALK-positive lymphomas.
- NPM-ALK activates Rac1 GTPase, promoting invadopodia formation and invasiveness in anaplastic large-cell lymphoma (ALCL).
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting Rac signaling in ALCL.
- To validate Rac GTPase as a molecular target in NPM-ALK-driven lymphomas.
Main Methods:
- Utilized the Rac inhibitor NSC23766 in vitro and in vivo.
- Employed xenograft and conditional NPM-ALK transgenic mouse models.
- Analyzed downstream effectors including Erk1/2, p38, and Akt.
Main Results:
- Rac inhibition abrogated NPM-ALK-induced transformation.
- NSC23766 treatment suppressed disease progression and metastasis in mouse models.
- Rac signaling regulates key effectors of NPM-ALK transformation.
Conclusions:
- Rac GTPase is a critical mediator of NPM-ALK oncogenic activity.
- Targeting Rac signaling presents a promising therapeutic strategy for ALK-positive lymphomas.
- Small GTPases and their regulators are viable targets for lymphoma treatment.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Abnormal Proliferation

